PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLIS	HED	UNDER THE PATENT COOPERATION TREATY (PCT)
(51) International Patent Classification 5:		(11) International Publication Number: WO 91/11206
A61L 15/28	A1	(43) International Publication Date: 8 August 1991 (08.08.91)
(21) International Application Number: PCT/GE (22) International Filing Date: 28 January 1991		(European patent), BF (OAPI patent), BG, BJ (OAPI
(30) Priority data: 9001878.9 26 January 1990 (26.01.9	0)_ (BE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR.
(71) Applicant (for all designated States except US) TECH LIMITED [GB/GB]; Tarvin Mill Inditate, Tarvin, Chester CH3 8JF (GB).): BEA Istrial	LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.
(72) Inventor; and (75) Inventor/Applicant (for US only): GILDING, Den [GB/GB]; Nepenthe, Wettenhall, Cheshire C (GB).	nis, Ke W7 41	ith DL Published With international search report.
(74) Agent: ATKINSON, Peter, Birch; Marks & Cl 301, Sunlight House, Quay Street, Manchester (GB).	erk, Su M3 3	Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ALGINATE MATERIALS

(57) Abstract

An alginate material useful particularly as a wound dressing incorporates cations selected from zinc, copper, silver, cerium, manganese, cobalt, or any cation which is an enzyme cofactor, save that the cation is not solely calcium, sodium or a mixture of these two cations.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

АŢ	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France		
BE	Belgium	GA	Gabon	MN	Mongolia
BF	Burkina Faso	GB	United Kingdom	MR	Mauritania
BG	Bulgaria	GN	Guinea Kinggom	MW	Malawi
BJ	Benin	-		NL	Netherlands
BR		GR	Greece	NO	Norway
	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JР	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic	SE	Sweden
CH	Switzerland		of Korea	SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	
cs	Czechoslovakia	LK	Sri Lanka		Chad
DE	Germany	LU		TG	Togo
DK	Denmark		Luxembourg	US	United States of America
~~	Dennia L	MC	Monaco		

1

Not the property of the control of t

ALGINATE MATERIALS

The present invention relates alginate materials which are useful particularly (but not exclusively) for wound dressings.

It is known that alginate materials have haemostatic and wound healing properties and may be used in various types of wound dressing (see for example EP-A- 0 236 104 (Courtaulds)).

Conventionally, alginates for wound dressings are prepared by spinning a solution of sodium alginate into a bath containing calcium ions (usually provided by calcium chloride) so that alginate material precipitates in the form of the insoluble calcium salt. For certain applications, it may be desirable for the alginate to have a greater degree of solubility in body fluids, in which case the calcium alginate may be treated in a bath of sodium ions so that some of the calcium is replaced by sodium to provide a more soluble form.

The alginates are highly hydrophilic and have thus found particular use in the dressing of "highly exuding" wounds where this absorbing allows comparatively large quantities of exudate to be absorbed before the alginate material dissolves.

It is a object of the present invention to provide alginate materials with improved properties for the treatment of wounds.

According to the present invention there is provide an alginate material which comprises of zinc, copper, silver, cerium, manganese, or cobalt cations and/or any cation which is an enzyme co-factor, save that the cation is not solely calcium, sodium or a mixture of these two cations. Enzyme co-factors include Mg²⁺, Co²⁺, Mn²⁺ and Fe³⁺ ions.

In the alginate material of the invention, the cation (or mixture of abovementioned cations) provide exchangeable

ions which have useful wound healing properties and the alginate serves as a base material for the delivery of these cations to the wound site. The absorbency of the alginate material is an added advantage.

Assuming that the cation has an oxidation slate of n+ the minimum amount of the cation incorporated in the alginate material is preferably (1/2n) moles (of cation) per mole of sugar residue in the alginate. Thus, for a divalent ion (n=2) the minimum amount is preferably 0.25 moles. Similarly for a monovalent ion (n=1) the preferred minimum amount is 0.5 moles (of cation). The preferred maximum amount for the cation is (1/n) moles per mole of sugar residue in the alginate. Thus the preferred maximum for divalent cation (n=2) is 0.5 moles.

The ions shown below have the indicated properties:

<u>Ion</u>	Wound Healing Property
Ion Zn ²⁺	promotes healing
Ag ⁺	bactericidal action
Cu ²⁺	anti-microbial, wound flushing
Ce ²⁺	anti-immunosuppressant
Mn ²⁺	enzyme (oxidase) co-factor
Co ²⁺	enzyme co-factor

It will thus be appreciated that alginate materials of the invention may be used in a wide range of wound healing applications. One particular application is for the treatment of leg ulcers which might contain in excess of 10⁵ organisms/ml. In this case, an alginate material containing copper ions may initially be applied to the ulcer and would cause the wound to flush itself. Subsequently, a further alginate material containing zinc ions may be applied to the ulcer to promote wound healing.

In order to assist delivery of the cations into the wound, it is possible to use an iontophoretic technique so as to "drive" the ions into the wound.

The alginate material may be in the form of a porous

WO 91/11206 PCT/GB91/00119

3

membrane but is more preferably in the form of a porous fibrous material or of a particulate material of sufficiently small size for formulation into an aerosol (which may then be sprayed onto a wound). The use of a porous fibrous material (produced, for example, as described below) is particularly advantageous because of the high internal surface are avoidable for ion-exchange.

Such a fibrous material may be produced by spinning a solution of a soluble alginate (particularly sodium or magnesium alginate) into bath containing the cations to be incorporated in the final alginate material. The solution may, for example, be spun into a bath by dissolving the chloride or nitrate of zinc and/or silver in water.

Such fibrous materials may be supported in any suitable way for application to a wound site. The support may, for example, comprise a porous textile dressing or a porous membrane or a porous polymeric membrane comprised of a hydrophobic polymer defining a porous (particularly microporous) structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer. Such a membrane is disclosed in WO-A-90/11820 (Beam Tech).

Particulate alginate material (for formulation into an aerosol) may be produced by subjecting particulate calcium alginate material to an ion exchange process with the appropriate cation(s).

An alginate membrane may be produced by preparing an aqueous solution of a soluble alginate material, forming the solution into the shape of a membrane, and treating the thus formed membrane precursor with a liquid containing cations which precipitate alginate material from solution as a porous membrane.

The precipitation bath may be aqueous or may be or include a water miscible organic solvent (e.g. DMSO, DMF).

WO 91/11206 PCT/GB91/00119

4

CLAIMS

1. An alginate material which incorporates cations selected from zinc, copper, silver, cerium, manganese, cobalt, or any cation which is an enzyme cofactor, save that the cation is not solely calcium, sodium or a mixture of these two cations.

Ŝ,

- 2. A material as claimed in claim 1 including an enzyme cofactor selected from Mg^{2+} , Co^{2+} , Mn^{2+} , and Fe^{3+} .
- 3. An alginate material as claimed in claim 1 or 2 wherein the alginate material is in the form of a fibre, a membrane, a film, or in the form of particles.
- 4. An alginate material as claimed in claim 3 wherein the alginate material comprises particles in the form of an aerosol.
- 5. A wound dressing comprising an alginate material as claimed in any one of claims 1 to 3.
- 6. A wound dressing as claimed in claim 4 wherein the alginate material is associated with a porous membrane comprised of a hydrophobic polymer defining the porous structure and a hydrophilic polymer provided at the surfaces, including the internal pore surfaces, of the hydrophobic polymer.
- 7. A method of producing an alginate material as claimed in claim 1 comprising providing a solution of a soluble alginate (preferably sodium or magnesium alginate) in a precipitation bath which contains at least one of said cations.
- 8. A method as claimed in claim 6 wherein said soluble alginate is spun into the bath to produce a fibre.
- 9. A method as claimed in claim 6 wherein said solution of the soluble alginate material is formed into the shape of a membrane and introduced into the precipitation bath.
- 10. A material as claimed in any one of claims 1 to 4 wherein the cation has an oxidation state of n+ and the amount of the cation present in the alginate material is at least (1/2n) moles per mole of sugar residue.

I. CLASSI	FICATION OF SUILJE	ECT MATTER (If several classification s	rombols analy indicate all to	
		Classification (IPC) or to both National (
Int.	C1. 5	A61L15/28		
İ				
II. FIELDS	SEARCHED			
		Minimum Docum	entation Searched?	
Classificat	tion System		Classification Symbols	
_				
Int.	C1. 5	A61L		
		Documentation Searched other	than Minimum Documentation	
		to the Extent that such Documents	are Included in the Fields Searched ⁸	
1				
1				
ļ				
		D TO BE RELEVANT ⁹		
Category °	Citation of Do	ocument, [1] with Indication, where appropri	ate, of the relevant passages 12	Relevant to Claim No.13
X	CD A 12	20000 (UNILAGE DAMEDO)		
[^	I IMITED	28088 (WALLACE, CAMERON) 30 August 1973	I AND COMPANY	1-5, 7
ļ		e 1, lines 38 - 53		
	see page	e 3, lines 5 - 24		
	see cla	ims 1-11	•	
х	EP.A.24	NOSNHOL & NOSNHOL) 6908	PRODUCTS THE Y	1.0
	28 Oct	ber 1987	reports inc.)	1-3, 5
	see page	e 2, lines 25 - 29; cla	ifms 1-14	
Α	CR A 074	 201 /CALMIC LINITED) 6	15 N 1 1001	
^	see clai	GB,A,976301 (CALMIC LIMITED) 25 November 1964 see claims 1-11		
				:
Α	GB, A, 629	9419 (JOHNSON & JOHNSON	LIMITED)	1
	20 Augu see clai	ist 1949	`	
	See Clai	IMS 1-14		
			-/	
			·	
		٠.		
	•			
° Special	categories of cited doc	iments : 10	"F" later downward will be to the	
"A" doc	ument defining the gen	eral state of the art which is not	"I" later document published after the internal or priority date and not in conflict with the	nantiantian but
con	stacted to be of particu	lar relevance shed on or after the international	cited to understand the principle or theory invention	
THIE	ig date	doubts on priority claim(s) or	"X" document of particular relevance; the claim cannot be considered novel or cannot be co	ned invention posidered to
WILL	in is cited to establish t	the publication date of another	involve an inventive step "Y" document of particular relevance; the claim	
"O" document referring to an oral disclosure, use, exhibition or			ve step when the	
"P" docs	er means ament published prior to	o the international filing date but	ments, such combination being obvious to in the art.	a person skilled
late	r than the priority date	claimed	"&" document member of the same patent fami	ly
IV. CERTIF				
Date of the	Actual Completion of the	e International Search	Date of Mailing of this International Searc	h Report
	24 AP	RIL 1991	3 D. 05. 91	İ
International	Searching Authority			
	•	N DATENIT GERICE	Signature of Authorized Officer	
	EURUPEA	N PATENT OFFICE	ESPINOSA Y CARR	
DCT/ISA	10 (second sheet) (lawren		<u> </u>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)						
Category °						
	or occurrently men	nucle appropria	ne, or the retevant passage	· · · · · · · · · · · · · · · · · · ·	Relevant to Claim No	
	GB,A,1255155 (WALL LIMITED) 01 Decemb see claims 1-18	LACE, CAMERON & Der 1971 	COMPANY		1	
				·		
				·		
:		÷	·			
		·		·		

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24/0 24/04/91

Patent document cited in search report	Publication date			Publication date	
GB-A-1328088	30-08-73	None			
EP-A-243069	28-10-87	AU-B- AU-A-	601726 7183187	20-09-90 22-10-87	
GB-A-976301		None			
GB-A-629419 .		None.			
GB-A-1255155	01-12-71	None None			

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82